The race to engineer cancer-fighting cells inside the human body—rather than in sterile labs thousands of miles away—claimed another well-funded contender this spring.
Vivacta Biotechnology, a Shanghai-based startup barely a year removed from its parent company, closed back-to-back financing rounds totaling north of $50 million on April 29, 2026, money the company says will push its experimental therapy through clinical trials and into regulatory review. The deal, split between a Series A led by Loyal Valley Capital and a Series A+ anchored by Decheng Capital, drew a roster of backers that reads like a who's who of life sciences investing: OrbiMed, Hankang Capital, Eisai Innovation, and C&D Emerging Industry Equity Investment all participated. Early investors Qiming Venture Partners, Shunxi Fund, and Apricot Capital doubled down.
It's a notable haul for a company that spun out of GRIT Biotechnology only last June—and one that speaks to the pharmaceutical industry's mounting impatience with the first generation of CAR-T therapies.
The $400,000 Problem
Traditional CAR-T treatment, for all its promise, remains a logistical nightmare. Doctors extract a patient's immune cells, ship them to a specialized facility (sometimes across continents), genetically reprogram them to hunt cancer, multiply them by the millions, then send them back for infusion. The process takes weeks, costs upward of $400,000 per patient in the U.S., and requires such intensive manufacturing that only a handful of facilities worldwide can manage it at scale.
Vivacta is betting on a different approach altogether. The company's lead candidate, GT801, uses lipid nanoparticles—think microscopic bubbles of fat—to deliver genetic instructions directly to T cells circulating in a patient's bloodstream. No extraction, no shipping, no month-long wait. The therapy programs the cells on the spot to attack CD19, a protein found on certain blood cancers.
Perhaps more intriguing: the treatment appears designed for repeat dosing without the harsh preparatory chemotherapy that typically precedes CAR-T infusions. If the approach pans out, it could fundamentally alter the economics and accessibility of cellular immunotherapy. Or it could join the long list of promising cancer treatments that stumbled somewhere between the lab and the clinic.
Early Signals, Cautious Optimism
At the American Society of Hematology's annual meeting in December 2025, Vivacta researchers presented data from two non-Hodgkin lymphoma patients who received multiple doses of GT801 in an investigator-led trial. Both achieved partial responses within four weeks—one after three doses of 0.5 milligrams, the other following four doses at 1.5 milligrams. The therapy appeared to hit its intended targets with minimal off-target effects, and both patients tolerated it well enough.
Two patients. Partial responses. It's the kind of early-stage data that venture investors find compelling and oncologists view with measured interest, understanding that the distance between promising and proven remains vast.
The company's technology leans on what it calls CLAMP—Controllable Ligand Attachment Modification and Purification—a proprietary method for attaching antibodies to nanoparticles with site-specific precision. Whether that translates to durable clinical benefit remains an open question.
A Sector Drawing Billions
Vivacta's fundraise arrives amid a scramble among pharmaceutical giants to acquire next-generation cell therapy platforms. Eli Lilly has been particularly aggressive. In February, the Indianapolis-based drugmaker announced plans to acquire Orna Therapeutics for up to $2.4 billion, gaining access to circular RNA technology for in vivo CAR-T development. Two months later, Lilly revealed an even larger bet: up to $7 billion for Kelonia Therapeutics and its lentiviral gene delivery system.
The message is unmistakable. After years of watching smaller biotechs pioneer the field, Big Pharma is buying its way in—fast.
At least eight in vivo CAR-T programs are now in clinical testing worldwide, with Bristol Myers Squibb, Johnson & Johnson, Gilead, AbbVie, Astellas, and AstraZeneca all jockeying for position. The field has the feel of a high-stakes land rush, where first-mover advantage could mean billions in eventual sales—or where multiple approaches might coexist, each suited to different cancers or patient populations.
What Comes Next
Vivacta plans to funnel the new capital into advancing GT801 through the clinic and preparing for regulatory submissions. The company is also expanding its R&D team and building out its platform technology—boilerplate startup language, perhaps, but necessary groundwork if the therapy proves viable.
More telling: Vivacta says it's focused on "accelerating global operations," a phrase that often signals either partnership discussions or plans to expand beyond home markets. For a Chinese biotech with international investors like OrbiMed aboard, both scenarios seem plausible.
A clinical trial for GT801 is recruiting patients with chronic lymphocytic leukemia, various B-cell lymphomas, B-cell acute lymphoblastic leukemia, and autoimmune hemolytic anemia at sites in Tianjin and Henan province, according to trial listings updated on April 20, 2026.
The company's board added Xie Ronggang from Loyal Valley Capital and a partner from Decheng's DC Global Ventures following the close—standard practice when new lead investors come aboard, though it does dilute the influence of Qiming Venture Partners, which led Vivacta's angel round of over 100 million RMB (roughly $14 million) in November 2025.
That angel round came just five months after Vivacta's spinout from GRIT Biotechnology in June 2025, an aggressive timeline that suggests either unusual investor confidence or founders eager to capitalize on a narrow window of opportunity in a suddenly hot sector. Likely both.
Whether Vivacta's approach ultimately delivers on its promise—or becomes another cautionary tale in cancer therapy development—will play out over the coming years in trial results and regulatory reviews. For now, it has capital, a clinical program underway, and the attention of investors convinced that the future of cell therapy won't require a FedEx shipment.
